A Comparitive Study on Efficacy and Safety of Vildagliptin-Metformin Versus Glimepiride-Metformin in Type 2 Diabetes Mellitus Patients

Authors

  • Prathap Bingi
  • Kareemulla Shaik Department of Pharmacy Practice, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh 516003
  • B. Himabindu
  • D. Sheklane Khan
  • G. Ramu
  • S. Mahammed Rafi

Keywords:

Type 2 diabetes, Metformin, Vildagliptin, Glimepiride, HbA1C, ADR’s

Abstract

Background: Inadequate control of blood glucose in patients may lead to micro or macro vascular complications. Metformin is initial drug used to treat diabetes. In case of inefficient glucose control with Metformin, add on therapy is recommended. The motto of our study is to compare efficacy and safety of Vildagliptin – Metformin with Glimepiride –Metformin in type 2 diabetes.

Methodology: A single centre prospective observational study conducted for 6 months in general medicine department at government general hospital, India. A total of 100 patients are recruited in study, divided into 2 groups containing 50 patients, who taking Vildagliptin with Metformin as group 1 and Glimepiride with Metformin as group 2. The data is collected, analyzed, summarized as averages. Figures are represented through graph pad prism by using Microsoft excel.

Results: HbA1C, FBS, RBS parameters are taken as primary and secondary end points to compare groups as per efficacy. Weight gain, hypoglycemia and other GI adverse effects are considered in terms of safety. The difference between values of baseline and final follow up of HbA1C, FBS, RBS are found to be 0.50%, 20mg/dl, 85mg/dl in group 1 (V-M); where as 0.35%, 15mg/dl, 55mg/dl in group 2 (G-M) respectively. 24 ADRs w.r.to hypoglycemia, weight gain, abdominal pain, muscle tenderness, diarrhoea are observed in group 1 (V-M) group and 46 ADRs are observed in group 2 (G-M).

Conclusion: Vildagliptin-metformin treatment provided favorable glucose control comparable to that of glimepiride-metformin treatment, resulted in better adverse event profiles with lower risks of hypoglycemia, weight gain.

Downloads

Download data is not yet available.

Downloads

Published

2022-05-09

How to Cite

Bingi, P. ., Shaik, K., Himabindu, B. ., Khan, D. S. ., Ramu, G. ., & Rafi, S. M. . (2022). A Comparitive Study on Efficacy and Safety of Vildagliptin-Metformin Versus Glimepiride-Metformin in Type 2 Diabetes Mellitus Patients. Indian Journal of Pharmacy & Drugs Studies, 1–6. Retrieved from https://mansapublishers.com/index.php/ijpds/article/view/3318

Issue

Section

Original Article